Effects of D-allulose on glucose tolerance and insulin response to a standard oral sucrose load: results of a prospective, randomized, crossover study
Open Access
- 26 February 2021
- journal article
- research article
- Published by BMJ in BMJ Open Diabetes Research & Care
- Vol. 9 (1), e001939
- https://doi.org/10.1136/bmjdrc-2020-001939
Abstract
Introduction Current dietary guidelines recommend limiting sugar intake for the prevention of diabetes mellitus (DM). Reduction in sugar intake may require sugar substitutes. Among these, D-allulose is a non-calorie rare monosaccharide with 70% sweetness of sucrose, which has shown anti-DM effects in Asian populations. However, there is limited data on the effects of D-allulose in other populations, including Westerners. Research design and methods This was a prospective, randomized, double-blind, placebo-controlled, crossover study conducted in 30 subjects without DM. Study participants were given a standard oral (50 g) sucrose load and randomized to placebo or escalating doses of D-allulose (2.5, 5.0, 7.5, 10.0 g). Subjects crossed-over to the alternate study treatment after 7–14 days of wash out. Plasma glucose and insulin levels were measured at five time points: before and at 30, 60, 90 and 120 min after ingestion. Results D-allulose was associated with a dose-dependent reduction of plasma glucose at 30 min compared with placebo. In particular, glucose was significantly lower with the 7.5 g (mean difference: 11; 95% CI 3 to 19; p=0.005) and 10 g (mean difference: 12; 95% CI 4 to 20; p=0.002) doses. Although glucose was not reduced at the other time points, there was a dose-dependent reduction in glucose excursion compared with placebo, which was significant with the 10 g dose (p=0.023). Accordingly, at 30 min D-allulose was associated with a trend towards lower insulin levels compared with placebo, which was significant with the 10 g dose (mean difference: 14; 95% CI 4 to 25; p=0.006). D-allulose did not reduce insulin at any other time point, but there was a significant dose-dependent reduction in insulin excursion compared with placebo (p=0.028), which was significant with the 10 g dose (p=0.002). Conclusions This is the largest study assessing the effects of D-allulose in Westerners demonstrating an early dose-dependent reduction in plasma glucose and insulin levels as well as decreased postprandial glucose and insulin excursion in subjects without DM. These pilot observations set the basis for large-scale investigations to support the anti-DM effects of D-allulose. Trial registration number NCT02714413.Keywords
This publication has 34 references indexed in Scilit:
- Sugar-Sweetened Beverages and Risk of Metabolic Syndrome and Type 2 DiabetesDiabetes Care, 2010
- Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular riskVascular Health and Risk Management, 2010
- Dietary Sugars Intake and Cardiovascular HealthCirculation, 2009
- Retraction: D-Psicose Inhibits Intestinal ^|^alpha;-Glucosidase and Suppresses the Glycemic Response after Ingestion of Carbohydrates in RatsJournal of Clinical Biochemistry and Nutrition, 2009
- Systematic review of randomized controlled trials of low‐carbohydrate vs. low‐fat/low‐calorie diets in the management of obesity and its comorbiditiesObesity Reviews, 2008
- Sugar-Sweetened Beverages and Incidence of Type 2 Diabetes Mellitus in African American WomenArchives of Internal Medicine, 2008
- Dietetic guidelines on food and nutrition in the secondary prevention of cardiovascular disease ? evidence from systematic reviews of randomized controlled trials (second update, January 2006)Journal of Human Nutrition and Dietetics, 2006
- Nutrition Recommendations and Interventions for Diabetes–2006Diabetes Care, 2006
- Izumoring: A novel and complete strategy for bioproduction of rare sugarsJournal of Bioscience and Bioengineering, 2004
- Mass production of d-psicose from d-fructose by a continuous bioreactor system using immobilized d-tagatose 3-epimeraseJournal of Bioscience and Bioengineering, 2000